With printed jet engines, cakes and even organs on the horizon, excitement for 3D printing is climbing quickly. The latest public 3D printing player, a small German maker of large, industrial-use systems, had the second best debut of the year for a US IPO,...read more
Ruthigen, an early stage biotech developing therapeutics to prevent and treat infection in surgical procedures, announced terms for its IPO on Wednesday. The Santa Rosa, CA-based company plans to raise $20 million by offering 1.5 million shares at a price range ...read more
Despite a downturn in the markets last week, the IPO market surged ahead, with nine deals pricing and two gaining more than 50%. Six of last week’s deals priced above their midpoints and seven traded up from their IPO prices, averaging a 22% gain at...read more
Ruthigen, a biotech developing therapeutics to prevent and treat infection in surgical and trauma procedures, filed on Thursday with the SEC to raise up to $27 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 2013,...read more
US IPO Recap: Voxeljet and Veeva vault up the charts
With printed jet engines, cakes and even organs on the horizon, excitement for 3D printing is climbing quickly. The latest public 3D printing player, a small German maker of large, industrial-use systems, had the second best debut of the year for a US IPO,...read more
Infection treatment biotech Ruthigen sets terms for $20 million IPO
Ruthigen, an early stage biotech developing therapeutics to prevent and treat infection in surgical procedures, announced terms for its IPO on Wednesday. The Santa Rosa, CA-based company plans to raise $20 million by offering 1.5 million shares at a price range ...read more
US IPO Recap: Nine deals price, Intrexon and Cvent soar
Despite a downturn in the markets last week, the IPO market surged ahead, with nine deals pricing and two gaining more than 50%. Six of last week’s deals priced above their midpoints and seven traded up from their IPO prices, averaging a 22% gain at...read more
Infection treatment biotech Ruthigen files for a $27 million IPO
Ruthigen, a biotech developing therapeutics to prevent and treat infection in surgical and trauma procedures, filed on Thursday with the SEC to raise up to $27 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 2013,...read more